Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

Our AbbVie (NYSE:ABBV | ABBV Price Prediction) call lands on the constructive side of the ledger after a noisy but encouraging Q1 earnings report. The 24/7 Wall St. price target for AbbVie is $229.32, implying 12.47% upside from the recent close of $203.89.

We rate ABBV a buy with high confidence (90%), driven by Skyrizi and Rinvoq momentum, raised guidance, and a forward multiple that has compressed back into reasonable territory.

24/7 Wall St. Price Target Summary

Q1 Results: Headline Noise, Underlying Strength

ABBV is down 9.3% year to date and 3.54% over the past month, sitting roughly 4% below the $239.13 52-week high.

Q1 2026 revenue came in at $15 billion, beating the $14.72 billion consensus and growing 12.43% YoY. Adjusted EPS of $2.65 missed by $0.02, but a $744 million IPR&D charge clipped $0.41 per share.

Management raised full-year adjusted EPS guidance to $14.08 to $14.28. Shares responded constructively, closing up 3.14% on the earnings report.

The Case for $250+

The bull case rests on AbbVie’s post-Humira pivot already working. Skyrizi grew 30.9% YoY to $4.48 billion, Rinvoq grew 23.3% to $2.12 billion, and the migraine franchise is on fire (Qulipta +53.6%, Ubrelvy +41.4%).

The pipeline adds optionality: a non-incretin obesity candidate, ABBV-295, showed clinically meaningful body weight reduction in early data, and Elahere posted a >60% objective response rate in platinum-sensitive ovarian cancer.

The Wall Street consensus target sits at $249.27 with 22 buy ratings and zero sells. Our bull-case scenario reaches $253.25, a 24.21% total return.

The Risks Worth Watching

Humira fell 38.6% YoY to $688 million, Imbruvica slid 24.7%, and the FDA issued a Complete Response Letter on trenibotulinumtoxinE over manufacturing.

GAAP net income fell 45.96% YoY, and the GAAP tax rate ran at 32.9%. That said, bulls would argue the GAAP weakness reflects deliberate IPR&D investment (the $744 million charge plus a $2.387 billion contingent consideration mark) rather than core earnings deterioration. Our bear-case price scenario lands at $206.69.

Why the Risk/Reward Skews Constructive

The 24/7 Wall St. price target of $229.32 represents a buy at 90% confidence. The tipping factor is the raised guidance combined with Skyrizi and Rinvoq each growing 20%+ on already huge bases. The setup looks constructive as long as the immunology growth engine stays intact and the obesity pipeline progresses through Phase 2.

I’d reconsider if Skyrizi or Rinvoq growth materially decelerates, or if additional manufacturing CRLs surface across the portfolio. CEO Robert Michael’s framing fits the data: “AbbVie’s key growth drivers continue to deliver strong performance and support our enhanced full-year outlook.”

AbbVie Price Prediction 2026-2030

These projections assume AbbVie continues executing on its Skyrizi and Rinvoq franchises while the obesity and oncology pipeline matures. Significant upside or downside could result from ABBV-295 obesity readouts, Skyrizi/Rinvoq biosimilar timelines later in the decade, or shifts in U.S. drug pricing policy.